Psoriasis (ARTISTYK Study)

Study Description

Brief Summary

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

Condition or Disease


Study Design

Study Type: Interventional
EstimatedĀ Enrollment: 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
ActualĀ Study Start Date: January 2023
EstimatedĀ Primary Completion Date: April 2024
EstimatedĀ Study Completion Date: January 2025

Eligibility Criteria

Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator. Deemed by the investigator to be a candidate for phototherapy or systemic therapy. ā‰„ 3% of Body Surface Area (BSA) involvement at Screening Visit and Day 1 Dermatology Life Quality Index (DLQI) score > 5 at Screening Visit and Day 1

Exclusion Criteria

Target Disease Exceptions: Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1 Other protocol-defined inclusion/exclusion criteria apply.